AIM  To evaluate clinical efficacy and safety of different lipid-lowering regimens in patients after percutaneous coronary intervention (PCI).

  METHODS  From January 2018 to July 2018, 104 patients with PCI planned were selected as study subjects and were randomly divided into a 10 mg rosuvastatin treatment group (n = 35), a 20 mg rosuvastatin treatment group (n = 35), and a 10 mg rosuvastatin +10 mg ezetimibe combined treatment group (n = 34). The patients were followed up for six months. Serum lipids were measured before and after treatment and compliance rate and adverse drug reactions were compared between the three groups.

  RESULTS  Levels of TC, LDL-C, oxLDL-C, oxLDL-C/TC, oxLDL-C/LDL-C and oxLDL-C/HDL-C were significantly lower than before in the three groups after treatment (P < 0.05). The extent of reduction of TC and LDL-C in the combined 10 mg rosuvastatin + ezetimibe group was significantly larger than those in the 10 mg rosuvastatin and 20 mg rosuvastatin groups (P < 0.05). The rate of attaining the standard of serum lipid in the combined 10 mg rosuvastatin +ezetimibe group was higher than those in the 10 mg rosuvastatin and 20 mg rosuvastatin groups, with statistically significant differences (P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the three groups (P < 0.05).

  CONCLUSION  The administration of rosuvastatin or the combined administration of rosuvastatin and ezetimibe in patients after percutaneous coronary intervention is safe and achieves beneficial effects in regulation of lipids and antioxidants and in attaining the standard of serum lipids.